Your session is about to expire
← Back to Search
Pembrolizumab for Breast Cancer
Study Summary
This trial will study how well pembrolizumab works in treating metastatic or recurrent inflammatory breast cancer or triple-negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My breast cancer is HER2 normal, and may or may not be inflammatory or triple negative.I have an immune system disorder or am on medication that weakens my immune system.I still have side effects from previous cancer treatments, except for mild neuropathy, hair loss, or general discomfort.I have had skin cancer or cervical cancer but it was treated with the intent to cure.I have stable brain metastases and haven't used steroids in the last 7 days.My cancer is HER2 negative based on specific tests.I haven't needed strong medication for an autoimmune disease in the last 3 months, except for minor conditions or stable hypothyroidism.I am using or willing to use effective birth control or abstain from sex during the study.My cancer is stage IV or has come back and has been treated.I have had pneumonitis treated with steroids or have it now.I am 18 years old or older.My cancer did not worsen after 2 months of chemotherapy for advanced or recurrent disease.I am fully active or restricted in physically strenuous activity but can do light work.I am currently being treated for an infection.I have been treated with specific immune-targeting drugs before.I have not received a live vaccine in the last 30 days.My blood and organ function tests are within the required ranges.I am currently receiving treatment for cancer that has spread.
- Group 1: Treatment (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current sample size of this clinical trial?
"Affirmative. Information on clinicaltrials.gov attests to the fact that this medical trial, initially posted on June 11th 2015, is currently enrolling participants. A total of 35 individuals are required at a single location."
Has the Federal Drug Administration given its approval to Pembrolizumab?
"Our team at Power gave Pembrolizumab a score of 2 on safety, since we only have preliminary information ensuring its security and not any data that can prove its efficacy."
Are there any openings available to join this clinical investigation?
"According to clinicaltrials.gov, this medical experiment is in the process of recruiting members for participation. It was initially posted on June 11th 2015 and has been updated as recently as September 7th 2022."
Has Pembrolizumab been tested in a research setting before?
"Currently, Pembrolizumab is the focus of 961 clinical trials worldwide. Of those studies, 122 are in their final phase and 35731 locations host these investigations. In particular, Houston Texas houses a significant portion of this research."
Share this study with friends
Copy Link
Messenger